Mechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

(2013) John B. Buse et al.   ANNALS OF INTERNAL MEDICINE

Clinical Diabetes/Therapeutics

(2012)   DIABETES

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

(2012) V. A. Fonseca et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings

(2012) J. J. Holst et al.   DIABETES OBESITY & METABOLISM

GLP-1 based therapies: differential effects on fasting and postprandial glucose

(2012) M.S. Fineman et al.   DIABETES OBESITY & METABOLISM

Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight

(2012) J. Jelsing et al.   DIABETES OBESITY & METABOLISM

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)

(2012) Y. Seino et al.   DIABETES OBESITY & METABOLISM

Impaired Secretion of Total Glucagon-like Peptide-1 in People with Impaired Fasting Glucose Combined Impaired Glucose Tolerance

(2012) Fang Zhang et al.   International Journal of Medical Sciences

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

(2012) Juris J. Meier   Nature Reviews Endocrinology

The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients

(2011) Anne Flint et al.   ADVANCES IN THERAPY

GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats

(2011) Lin Wu et al.   CLINICAL SCIENCE

Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans

(2011) M. A. Nauck et al.   DIABETES

Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes

(2011) Mary Beth DeYoung et al.   Diabetes Technology & Therapeutics

Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes

(2011) J. Ma et al.   DIABETIC MEDICINE

Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: Relationship to glycemia*

(2010) Adam M. Deane et al.   CRITICAL CARE MEDICINE

In Vivo Expression of HGF/NK1 and GLP-1 From dsAAV Vectors Enhances Pancreatic  -Cell Proliferation and Improves Pathology in the db/db Mouse Model of Diabetes

(2010) D. F. Gaddy et al.   DIABETES

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results

(2009) Sten Madsbad   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Glucagon-Like Peptide-1 Protects  -Cells Against Apoptosis by Increasing the Activity of an Igf-2/Igf-1 Receptor Autocrine Loop

(2009) M. Cornu et al.   DIABETES

Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials

(2009) Matteo Monami et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Exenatide once weekly for the treatment of type 2 diabetes

(2009) James Malone et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Endogenous Glucagon-Like Peptide-1 Slows Gastric Emptying in Healthy Subjects, Attenuating Postprandial Glycemia

(2009) Adam M. Deane et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Adding Liraglutide to Oral Antidiabetic Drug Monotherapy: Efficacy and Weight Benefits

(2009) Michael Nauck et al.   POSTGRADUATE MEDICINE

A Stable Isotope Breath Test With a Standard Meal for Abnormal Gastric Emptying of Solids in the Clinic and in Research

(2008) Lawrence A. Szarka et al.   Clinical Gastroenterology and Hepatology

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

(2008) P. V. Højberg et al.   DIABETOLOGIA

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

(2008) Helle Linnebjerg et al.   REGULATORY PEPTIDES